Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-103292
Filing Date
2025-10-28
Accepted
2025-10-28 17:39:57
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 12667
  Complete submission text file 0001104659-25-103292.txt   14419
Mailing Address 7TH FLOOR, CHEUNG KONG CENTER 2 QUEEN'S ROAD CENTRAL CENTRAL K3 -
Business Address 7TH FLOOR, CHEUNG KONG CENTER 2 QUEEN'S ROAD CENTRAL CENTRAL K3 - 852 2128 8888
CK Life Sciences Intl (Holdings) Inc (Filed by) CIK: 0001297567 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Subject) CIK: 0001829635 (see all company filings)

EIN.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92695 | Film No.: 251426066
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)